Clinical Data Establish Role of Triplet Therapies in Relapsed Multiple Myeloma
August 24th 2020Shagun D. Arora, MD, discusses findings from the phase 3 CANDOR, ICARIA-MM, and IKEMA studies which solidified the role of triplet regimens versus doublets in the relapsed/refractory multiple myeloma treatment landscape.
Dr. Shah on the Role of Venetoclax in Multiple Myeloma
April 23rd 2020Nina Shah, MD, associate professor of medicine, Department of Medicine, at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the role of venetoclax (Venclexta) in multiple myeloma.
COVID-19 Is "Biggest Medical Issue" of Modern Times, Rugo Says
March 20th 2020The need to establish preventive procedures that keep pace with the rapid evolution of coronavirus 2019 presents numerous challenges for the oncology field as institutions adapt standard treatment protocols to minimize the risk for virus spread among clinicians and patients alike.
Dr. Fakhri on Ongoing Clinical Trials in CLL
February 18th 2020Bita Fakhri, MD, MPH, assistant professor of medicine in the Division of Hematology/Oncology at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses ongoing clinical trials in chronic lymphocytic leukemia (CLL).
Dr. Kaplan on the Use of PI3K Inhibitors in Follicular Lymphoma
February 8th 2020Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, Division of Hematology-Oncology, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the use of PI3K inhibitors in follicular lymphoma.
Dr. Shah on Potential for Daratumumab Maintenance in Multiple Myeloma
February 7th 2020Nina Shah, MD, associate professor of medicine, Department of Medicine, at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the potential for daratumumab (Darzalex) maintenance therapy in multiple myeloma.